Immune checkpoint inhibitors (ICIs) are a newly developed component of cancer care that
expands the treatment possibilities for patients. Their use has been associated with several …

Background Immune checkpoint therapy has dramatically changed the landscape of cancer
therapy, providing an efficacious and durable therapeutic option for patients with advanced …

Immune checkpoint inhibitors (ICPIs) have emerged as a frontline treatment for a growing list
of malignancies. Disruption of the negative regulatory immune checkpoints by ICPIs has …

Immune checkpoint inhibitors show remarkable antitumor activity across multiple tumor
types, with approval of programmed death–1 (PD-1) inhibitors for non–small cell lung cancer …

Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and
programmed cell death-1 receptors have transformed the treatment of melanoma and other …

Immunotherapy with checkpoint inhibitors has revolutionized the management of metastatic
melanoma. These checkpoints, namely the cytotoxic T lymphocyte antigen 4 and the …

Simple Summary Granulomatosis is commonly observed in patients receiving immune
checkpoint inhibitors (ICIs) for melanoma and other cancers. Recognizing this reaction early …

Sarcoidosis and sarcoid‐like reactions (SLRs) may develop in association with various
malignancies, as well as in association to certain oncologic drugs, including immune …

Immune checkpoint inhibitors (CPIs) have recently become a cornerstone for the treatment
of different advanced cancers. These drugs have the ability to reactivate the immune system …

Therapy for advanced melanoma has deeply changed in the last decade with the
introduction of checkpoint and BRAF/MEK inhibitors. Granulomatous reactions have been …